Sir:
Chemical modification of kanamycin antibiotics on the basis of the biochemical mechanism of resistance has afforded derivatives which are active against resistant bacteria including Pseudomonas aeruginosa. These analogs, which include 3',4'-dideoxykanamycin B (dibekacin)1)° and I -N-[(S) -4 -amino-2 -hydroxybutyryl] kanamycin (amikacin)2) have been widely used in treatment of resistant infections. Enzymes involved in these resistance mechanisms transfer the phosphoryl or adenylyl group from ATP to a hydroxyl group of the aminoglycoside or the acetyl group from acetyl CoA to an amino group. Therefore, these enzymes should have two binding sites, the one to the adenosine moiety of ATP or acetyl CoA and the other to aminoglycosides. It suggests that these enzymes should have close evolutional relationships and in the future, new enzymes which transfer phosphoryl or adenylyl groups to the 2'-, 4"-and 6"-hydroxyl groups of kanamycin and its derivatives may appear. Considering this possibility, the authors were interested in the structure of the active derivative which has the least number of hydroxyl groups. In order to reach this objective we have synthesized polydeoxy compounds of the kanamycin antibiotics starting from dibekacin (1), 1-N-[(S)-4-amino-2-hydroxybutyryl] dibekacin3) (2), amikacin (3), and 3',4'-dideoxyamikacin4) (4) . We wish to report the preparation of the following polydeoxy analogs: 4", 6"-dideoxydibekacin (3',4',4",6"-tetradeoxykanamycin B, 5), 6"-deoxydibekacin
(9), 6"-deoxyamikacin (10), 3',4',4",6"-tetradeoxyamikacin (11) and 3',4',6"-trideoxyamikacin (12). All of them showed a good activity against Gram-positive and negative bacteria except against Pseudomonas aeruginosa.
The free amino groups of I were protected with the tert-butoxycarbonyl (Boc) group by reaction with tert-butyl S-4,6-dimethylpyrimid-2-ylthiocarbonate in a mixture of methanol, water and triethylamine at 60'C for 5 hours to afford 1,3,2',6',3 "-penta -N -Boc -dibekacin (13) in 75% yield. Compound 13 was treated with 1,1-dimethoxycyclohexane in N,N-dimethylformamide in the presence of p-toluenesulfonic acid at room temperature for 16 hours to yield 1,3,2',6',3 "-penta-N -Boc-4",6" -O -cyclohexylidenedibekacin (14) in quantitative yield.
Benzoylation of 14 with benzoyl chloride in pyridine overnight at 60°C gave 2"-O-benzoyl-I ,3,2',6',3 "-penta-N -Boc-4",6"-O -cyclohexylidenedibekacin (15, 95% yield). Hydrolysis of the O-cyclohexylidene group in 15 with a mixture of acetic acid, methanol and water (2: 1 : 1) at 40-50'C for 4 hours followed by chloroform
Mesylation of 16 with 2.4 equivalents of methanesulfonyl chloride in pyridine overnight at 30°C followed by silica gel column chromatography (chloroform-ethanol, 50: 1) afforded the 4", 6"-di-O-mesyl derivative 17 in 20 % yield and the 6"-O-mesyl derivative 18 in 47% yield. Compound 17 was also obtained in 88%, yield by mesylation of 16 with 5 equivalents of methanesulfonyl chloride at 40-50'C.
Compound 17 was treated with an excess of sodium iodide in N,N-dimethylformamide at 95°C for 5 hours under argon atmosphere to yield the 4",6"-di-iodo derivative 19 (57% yield), which was purified by preparative TLC on silica gel plates (chloroform -ethanol, 20: 1). Dehalogenation of 19 by catalytic hydrogenation with RANEY-Ni in dioxane in a PARR apparatus (3.6 kg/cm2), debenzolyation with 12% ammonia in methanol, removal of the Boc groups with 90% trifluoroacetic acid, followed by column chromatography on Amberlite CG-50 (NH4+) resin and elution with 0.4 N ammonia gave 4",6"-dideoxydibekacin (5) as the sesquicarbonate salt in 52 % yield from 19.
Halogenation of 18 with sodium iodide, dehalogenation of the 6"-iodide 20 by catalytic hydrogenation, removal of the 0-and N-protective groups by hydrolysis with 12% ammonia in methanol and then with 90% trifluoroacetic acid, followed by column chromatography on Amberlite CG-50 resin gave 6"-deoxydibekacin (6) as the sesquicarbonate salt in 75 % yield from 18.
By the similar synthetic route, the 1-N-[(S)-4-amino-2-hydroxybutyryl] derivatives (7 and 8)
of compounds 5 and 6 were synthesized from Table 1 . Properties of the 6"-deoxy and 4",6"-dideoxy derivatives.
Compound The properties of the eight compounds described above are shown in Table I . Although only two compounds (5 and 6) showed M+ ions in MS spectra, the structures of all compounds were confirmed by analysis of fragmentations of the 2-deoxystreptamine moiety5) (m/e 191, 163
and 145) and the aminohexose moieties ( Table 1) .
The minimum inhibitory concentrations of the polydeoxy derivatives (5 -12) are shown in Table  2 in comparison with those of dibekacin (1) 
